Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial

Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial

Veure altres versions (1)

Background: OXi4503 is a tubulin-binding vascular disrupting agent that has recently completed a Cancer Research UK-sponsored phase I trial. Preclinical studies demonstrated early drug-induced apoptosis in tumour endothelial cells at 1-3 h and secondary tumour cell necrosis between 6 and 72 h. Metho...

Descripció completa

Dades bibliogràfiques
Autors principals:	Cummings, J, Zweifel, M, Smith, N, Ross, P, Peters, J, Rustin, G, Price, P, Middleton, MR, Ward, T, Dive, C
Format:	Journal article
Idioma:	English
Publicat:	2012

Ítems similars

Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial.
per: Cummings, J, et al.
Publicat: (2012)

Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors.
per: Patterson, D, et al.
Publicat: (2012)

Validation of a method for the determination of the anticancer agent Combretastatin A1 phosphate (CA1P, OXi4503) in human plasma by HPLC with post-column photolysis and fluorescence detection.
per: Stratford, MR, et al.
Publicat: (2011)

Validation of a method for the determination of the anticancer agent Combretastatin A1 phosphate (CA1P, OXi4503) in human plasma by HPLC with post-column photolysis and fluorescence detection
per: Stratford, M, et al.
Publicat: (2011)

4503 Adaptation of Motor Action in Children with Hemiplegic Cerebral Palsy
per: Katherine Dimitropoulou, et al.
Publicat: (2020-06-01)

Quantitative determination of the anticancer prodrug combretastatin A1 phosphate (OXi4503, CA1P), the active CA1 and its glucuronide metabolites in human urine and of CA1 in plasma by HPLC with mass spectrometric detection.
per: Stratford, MR, et al.
Publicat: (2012)

Use of In Vitro and Predictive In Silico Models to Study the Inhibition of Cytochrome P4503A by Stilbenes.
per: Loai Basheer, et al.
Publicat: (2015-01-01)

Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents.
per: Shaked, Y, et al.
Publicat: (2009)

SA4503 Mitigates Adriamycin-Induced Nephropathy via Sigma-1 Receptor in Animal and Cell-Based Models
per: Hideaki Tagashira, et al.
Publicat: (2025-01-01)

Vascular disrupting agent drug classes differ in effects on the cytoskeleton.
per: Sujeong Kim, et al.
Publicat: (2012-01-01)

Risk assessment of drug–drug interaction potential for bintrafusp alfa with cytochrome P4503A4 substrates: A totality of evidence approach
per: Yulia Vugmeyster, et al.
Publicat: (2022-12-01)

Tumour vascular disrupting agents: combating treatment resistance.
per: Tozer, G, et al.
Publicat: (2008)

Saint John's wort, an herbal inducer of the cytochrome P4503A4 isoform, may alleviate symptoms of Willis-Ekbom's disease
per: José Carlos Pereira Jr, et al.
Publicat: (2013-04-01)

Drug metabolism in human brain: high levels of cytochrome P4503A43 in brain and metabolism of anti-anxiety drug alprazolam to its active metabolite.
per: Varsha Agarwal, et al.
Publicat: (2008-06-01)

Corrigendum: The Reversal Effect of Sigma-1 Receptor (S1R) Agonist, SA4503, on Atrial Fibrillation After Depression and Its Underlying Mechanism
per: Xin Liu, et al.
Publicat: (2022-04-01)

Limitation of Irregularities in Projects Co-financed by EU Funds. Gloss to the Judgement of the Supreme Administrative Court of 18 May 2017 (II GSK 4503/10)
per: Rafał Poździk
Publicat: (2020-06-01)

4-Hydr-oxy-3-nitro-benzaldehyde.
per: Rizal, M.R., et al.
Publicat: (2008)

Targeting vascular disrupting agent-treated tumor microenvironment with tissue-penetrating nanotherapy
per: Valeria Sidorenko, et al.
Publicat: (2024-07-01)

Parallel kinetic resolution of tert-butyl (RS)-3-oxy-substituted cyclopent-1-ene-carboxylates for the asymmetric synthesis of 3-oxy-substituted cispentacin and transpentacin derivatives.
per: Aye, Y, et al.
Publicat: (2008)

Anti-Inflammatory Oxysterol, Oxy210, Inhibits Atherosclerosis in Hyperlipidemic Mice and Inflammatory Responses of Vascular Cells
per: Frank Stappenbeck, et al.
Publicat: (2024-09-01)

1-De-oxy-l-mannitol (6-de-oxy-l-mannitol or l-rhamnitol).
per: Jenkinson, S, et al.
Publicat: (2008)

Antitumor effect of the vascular-disrupting agent ZD6126 in a murine renal cell carcinoma model.
per: Medinger, M, et al.
Publicat: (2011)

Quantifying the evolution of vascular barrier disruption in advanced atherosclerosis with semipermeant nanoparticle contrast agents.
per: Huiying Zhang, et al.
Publicat: (2011-01-01)

Oxy-Hydrogen Flame for Cutting of Steels
per: Tušek, J., et al.
Publicat: (2007-01-01)

Dynamic-Stability Characteristics of Premixed Methane Oxy-Combustion
per: Shroll, Andrew P, et al.
Publicat: (2021)

Neutrophil Influx and Chemokine Production during the Early Phases of the Antitumor Response to the Vascular Disrupting Agent DMXAA (ASA404)
per: Liang-Chuan S. Wang, et al.
Publicat: (2009-08-01)

Treatment Effect of a Vascular-Disrupting Agent Dynamically Monitored by DWI: An Animal Experimental Study
per: Danping Huang, et al.
Publicat: (2021-01-01)

Evaluation of the antitumor activity of NOV202, a novel microtubule targeting and vascular disrupting agent
per: Rickardson L, et al.
Publicat: (2017-04-01)

Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines
per: Hung Chien-Fu, et al.
Publicat: (2011-03-01)

Mechanisms of tumor resistance to small-molecule vascular disrupting agents: Treatment and rationale of combination therapy
per: Xue-Yuan Wu, et al.
Publicat: (2013-03-01)

Non-Invasive Evaluation of Acute Effects of Tubulin Binding Agents: A Review of Imaging Vascular Disruption in Tumors
per: Li Liu, et al.
Publicat: (2021-04-01)

2-Hydroxy-5-nitrobenzaldehyde thiosemicarbazone
per: Alhadi, Abeer A., et al.
Publicat: (2008)

Resilience and ductility of Oxy-fuel HAZ cut
per: A. Martín-Meizoso,, et al.
Publicat: (2014-10-01)

Resilience and ductility of Oxy-fuel HAZ cut
per: A. Martín-Meizoso, et al.
Publicat: (2014-09-01)

Oxy-acetylene welding and cutting/
per: Giachino, Joseph William, 1906-
Publicat: (1942)

Oxy-Acetylene welding [filem]
Publicat: ([197)

Oxy-acetylene welding [videorecording]
per: Safetycare Australia
Publicat: (2010)

Oxy acetylene cutting [videorecording]
Publicat: (2010)

Oxy-acetylene welding handbook
Publicat: ([n d)

ẢNH HƯỞNG CỦA OXY HÒA TAN LÊN TĂNG TRƯỞNG, TIÊU HAO OXY VÀ NGƯỠNG OXY CỦA CÁ CHÉP (CYPRINUS CARPIO)
per: Nguyễn Thúy Liễu, et al.
Publicat: (2012-05-01)